联合应用成纤维细胞介导的G-CSF基因疗法及IL-2基因疗法对肿瘤的治疗作用

The Therapeutic Effects Of Combined Fibroblast-Mediated IL-2 and G-CSF Gene Therapy on Tumor-Bearing Mice

本研究探讨了成纤维细胞介导的G-CSF基因疗法联合应用IL-2基因疗法及时对小鼠Ⅰ期肾癌的治疗作用。经NIH3T3-IL-2基因疗法、NIH3T3-G-CSF基因疗法单独治疗后的荷瘤小鼠存活期明显延长,而经以上两者联合治疗后的荷瘤小鼠存活期的延长更为明显,且有75％荷瘤小鼠长期存活。对经G-CSF基因疗法及IL-2基因疗法联合治疗后的荷瘤小鼠体内抗肿瘤免疫功能的检测表明,经治疗后第14天,荷瘤小鼠脾脏明显增大,脾脏淋巴细胞数量明显增多;肿瘤局部的常规病理检查可见数量较多的嗜酸性粒细胞浸润。荷瘤小鼠脾细胞NK活性、经诱导后的LAK活性及CTL杀伤活性均明显升高,小鼠腹腔巨噬细胞杀伤活性在NIH3T3-IL-2基因疗法治疗组升高,而在NIH3T3-G-CSF基因疗法组未见明显升高。以上结果表明,联合应用成纤维细胞介导的G-CSF基因疗法与IL-2基因疗法可因对小鼠体内抗肿瘤免疫功能的联合增强作用而取得更佳的抗肿瘤效果。

The Renca-bearing mice were treated by combined fibroblast-mediated IL-2 and G-CSF gene therapy. The survival periods of Renca-bearing mice were prolonged markedly and 75% of Renca-bearing mice were cured. The spleens of Renca-bearing mice treated by fibroblast-mediated G-CSF gene therapy were larger than the spleens of other mice. Histologic analysis of tumor showed that there were a number of infiltrating eosinophils. The NK, LAK and CTL activity induced from the splenocytes of the tumor-bearing mice increased siginificantly when the mice were treated by fibroblast-mediated IL-2 gene therapy and the cytotoxicity of macrophages also increased. The results demonstrated that the and - tumor responses might be induced more significantly by combined fibroblast-mediated IL-2 and G-CSF gene therapy and better antitumor effect may be achieved.